<p>辉瑞（<strong>NYSE: PFE</strong>）的股价在过去一个月上涨了 8.24%，将其年初至今的损失减少至 5.02%。在过去一年中，PFE 的股价下跌了 8.75%。最近，FDA 宣布将仅推荐 65 岁及以上的老年人和某些医疗条件患者接种 COVID-19 疫苗，排除了健康成年人和某些年龄以上的儿童。这可能对辉瑞造成严重的逆风，其新冠病毒相关产品——Paxlovid 和 Comirnaty——在 2024 年贡献了 111 亿美元的总收入。</p>
<p>尽管 2024 年年末的业绩强劲，辉瑞在 2025 年仍在寻找立足之地，这得益于其 COVID 产品以及非 COVID 产品（如 Vyndaquel、Padcev 和 Eliquis）的销售超出预期。这家成立 176 年的大型制药公司在其行业中处于领先地位。辉瑞长期以来以大规模生产抗寄生虫药物 santonin、青霉素和抗生素而闻名，20 世纪后期辉瑞发明了伟哥（治疗勃起功能障碍）、佐洛夫（抗抑郁药）和立普妥（降胆固醇药物），使公司市值达到数千亿美元。</p>
<p>但在过去五年中，尽管辉瑞支付了当前收益率为 6.81% 的股息，股票仍让股东失望。在此期间，辉瑞的股价下跌超过 31%，自 2021 年 12 月 17 日的历史高点以来，PFE 的股价下跌超过 57%。<strong>24/7 Wall St.</strong> 进行了分析，以为潜在投资者提供对未来五年股票走势的想法。</p>
<p><img src="https://imageproxy.pbkrs.com/https://247wallst.com/wp-content/uploads/2025/01/Follow-Our-500000-AI-Portfolio-3.jpg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://247wallst.com/wp-content/uploads/2025/01/Follow-Our-500000-AI-Portfolio-3.jpg"/></p>
<h2>本文的关键点：</h2>
<ul>
<li>辉瑞预测 2025 财年的总收入将在 610 亿美元至 640 亿美元之间，新获得的药物将填补 COVID 产品（如 Paxlovid）滞后的空缺。</li>
<li>肿瘤学销售预计将增长，约占公司收入的 25%，有多种药物不仅在研发中，还处于后期开发阶段。</li>
<li>如果您正在寻找具有巨大潜力的重大趋势，请确保获取我们 <strong>“下一个 NVIDIA” 报告</strong> 的免费副本。该报告详细分析了具有 10 倍潜力的 AI 股票，并将为您在这一重大变革中获利提供巨大的帮助。</li>
</ul>
<h2>辉瑞近期股票成功</h2>
<p>作为一家传统制药公司，辉瑞是家喻户晓的名字，既是买入持有型投资组合的固定成分，也是收入型投资组合的常客。在 2024 年，公司通过股息直接向股东返还了 95 亿美元。在过去 40 年中，辉瑞的股价上涨了 1139%。2014 年，辉瑞收购了 Innopharma 和 Baxter International 的疫苗组合。2016 年，它收购了 Anacor Pharmaceuticals。2019 年，公司收购了 Therachon。然而，在过去三年中，辉瑞的股价表现不佳。</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>财年</strong></td>
<td><strong>价格</strong></td>
<td><strong>收入</strong></td>
<td><strong>净收入</strong></td>
</tr>
<tr>
<td>2015</td>
<td>$30.63</td>
<td>$48.851 B</td>
<td>$6.960 B</td>
</tr>
<tr>
<td>2016</td>
<td>$30.82</td>
<td>$52.824 B</td>
<td>$7.215 B</td>
</tr>
<tr>
<td>2017</td>
<td>$34.36</td>
<td>$52.546 B</td>
<td>$21.308 B</td>
</tr>
<tr>
<td>2018</td>
<td>$41.41</td>
<td>$40.825 B</td>
<td>$11.153 B</td>
</tr>
<tr>
<td>2019</td>
<td>$37.17</td>
<td>$40.905 B</td>
<td>$16.026 B</td>
</tr>
<tr>
<td>2020</td>
<td>$36.81</td>
<td>$41.651 B</td>
<td>$9.159 B</td>
</tr>
<tr>
<td>2021</td>
<td>$59.05</td>
<td>$81.288 B</td>
<td>$21.979 B</td>
</tr>
<tr>
<td>2022</td>
<td>$51.24</td>
<td>$100.330 B</td>
<td>$31.372 B</td>
</tr>
<tr>
<td>2023</td>
<td>$28.79</td>
<td>$58.496 B</td>
<td>$2.119 B</td>
</tr>
<tr>
<td>2024</td>
<td>$26.53</td>
<td>$55.166 B</td>
<td>-$2.595 B</td>
</tr>
</tbody>
</table>
<p>在 COVID-19 出现之前的五年中，PFE 的股价上涨了 20.17%。作为疫情疫苗竞赛的三大赢家之一，该股在 2021 年大幅上涨，年末时上涨了 60.41%。但自 2022 年底以来，这一效应逐渐消退，股价回落。然而，有一些顺风因素可能会使辉瑞的股价在未来几年反弹。</p>
<h2>辉瑞股票表现的关键驱动因素</h2>
<p><strong>1. 摆脱 COVID 的影响：</strong> 在 2024 年第四季度的财报电话会议上，首席财务官 Dave Denton 表示：“我们的收入波动性在很大程度上已经过去，因为与 COVID 相关的不确定性已经减少。” 随着 COVID 病例持续下降，公司能够重新聚焦（并重新分配资本支出）于一系列非 COVID 和肿瘤药物——Denton 表示，这预计将 “为持续的利润扩张奠定基础。” 辉瑞正在开发多种珍贵的肿瘤药物，该药物市场预计将在 2025 年至 2030 年间实现 8.1% 的复合年增长率（CAGR）。此外，公司非 COVID 药物产品在 2024 年增长了 12%，超出了 9% 至 11% 的指导范围。</p>
<p><strong>2. 肥胖药物需求的扩大：</strong> 尽管辉瑞在肥胖药物领域的进入较晚，导致其将相当大的市场份额让给了诺和诺德的 Ozempic，但辉瑞已推进其每日一次口服制剂_dangulipron_的开发。公司将肥胖视为未来的一个关键治疗领域。肥胖药物行业预计将在 2025 年至 2030 年间实现 22.3% 的显著复合年增长率。</p>
<p><strong>3. 联合营销药物：</strong> 辉瑞与百时美施贵宝合作，共同营销抗凝血药物 Eliquis。这一合作在 2024 年第四季度带来了 18.3 亿美元的收入，同比增长 14%，超出了分析师预期的 16.7 亿美元。抗凝血药物市场在 2023 年的估值为 348 亿美元，预计在 2024 年至 2030 年间实现 10.2% 的复合年增长率。</p>
<p><img src="https://imageproxy.pbkrs.com/https://247wallst.com/wp-content/uploads/2022/01/imageForEntry4-6PZ.jpg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://247wallst.com/wp-content/uploads/2022/01/imageForEntry4-6PZ.jpg"/></p>
<h2>辉瑞（PFE）2025-2030 年价格预测</h2>
<p>根据分析师的共识，辉瑞当前的一年价格目标为 28.38 美元，这代表着在未来 12 个月内相较于 PFE 当前股价的 12.26% 的潜在上涨。在覆盖辉瑞的 18 位分析师中，该股获得了 “适度买入” 的共识评级，其中 5 位分析师给予 “买入” 评级，13 位给予 “持有” 评级，0 位给予 “卖出” 评级。</p>
<p>然而，到 2025 年底，<strong>24/7 Wall St.</strong> 的预测显示辉瑞的股票将以 33.60 美元的价格交易，基于预计每股收益（EPS）为 2.80 美元和前瞻市盈率（P/E）为 7.53。这个价格目标相较于今天的股价有 32.91% 的潜在上涨空间。</p>
<h2>辉瑞股票价格目标到 2030 年</h2>
<p>根据我们的分析，<strong>24/7 Wall St.</strong> 预测辉瑞的股票到 2030 年底将以 34.08 美元的价格交易。这个价格目标相较于今天的股价有 34.81% 的潜在上涨空间。</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>年份</strong></td>
<td><strong>价格</strong></td>
<td><strong>与当前价格的变化百分比</strong></td>
</tr>
<tr>
<td>2025</td>
<td>$33.60</td>
<td>32.91%</td>
</tr>
<tr>
<td>2026</td>
<td>$36.00</td>
<td>42.40%</td>
</tr>
<tr>
<td>2027</td>
<td>$36.72</td>
<td>45.25%</td>
</tr>
<tr>
<td>2028</td>
<td>$33.24</td>
<td>31.48%</td>
</tr>
<tr>
<td>2029</td>
<td>$32.64</td>
<td>29.11%</td>
</tr>
<tr>
<td>2030</td>
<td>$34.08</td>
<td>34.81%</td>
</tr>
</tbody>
</table>
<p>关于辉瑞公司（NYSE: PFE）2025-2030 年价格预测和展望的文章首次出现在 24/7 Wall St.上。</p>

辉瑞

<p>辉瑞公司（NYSE: PFE）在过去一个月的股价上涨了 8.24%，将其年初至今的亏损减少至 5.02%。然而，过去一年该股下跌了 8.75%。美国食品药品监督管理局（FDA）最近的建议将 COVID-19 疫苗的接种限制在老年人和特定病症患者，这给辉瑞的 COVID 产品收入带来了挑战。尽管 COVID 和非 COVID 产品的销售强劲，但该股在过去五年中下跌超过 31%。辉瑞预计 2025 财年的收入将在 610 亿美元到 640 亿美元之间，主要受肿瘤学销售和新药收购的推动</p>

<p>Shares of <strong>Pfizer (</strong> <strong>NYSE: PFE</strong> <strong>)</strong> surged 8.24% over the past month, reducing the stock’s year-to-date loss to 5.02%. Over the past year, PFE has fallen by 8.75%. Recently, the FDA announced it will only be recommending COVID-19 vaccines for seniors aged 65 and older and those with certain medical conditions, excluding healthy adults and children above a certain age from its recommendation. That may act as a severe headwind for Pfizer, whose coronavirus franchise — Paxlovid and Comirnaty — contributed $11.1 billion in combined revenue in 2024.</p>
<div class="lb-trans"><p>辉瑞（<strong>NYSE: PFE</strong>）的股价在过去一个月上涨了 8.24%，将其年初至今的损失减少至 5.02%。在过去一年中，PFE 的股价下跌了 8.75%。最近，FDA 宣布将仅推荐 65 岁及以上的老年人和某些医疗条件患者接种 COVID-19 疫苗，排除了健康成年人和某些年龄以上的儿童。这可能对辉瑞造成严重的逆风，其新冠病毒相关产品——Paxlovid 和 Comirnaty——在 2024 年贡献了 111 亿美元的总收入。</p>
</div><p>Pfizer continues to search for its footing in 2025 despite strong year-end 2024 results driven by stronger-than-expected sales from its COVID products, as well as its non-COVID products, such as Vyndaquel, Padcev and Eliquis. The 176-year-old Big Pharma mainstay has been at the forefront of its industry for several decades. Long known for its mass production of santonin (an antiparasitic drug), penicillin, and antibiotics, the latter part of the 20th century saw Pfizer invent Viagra (erectile dysfunction), Zoloft (anti-depressant) and Lipitor (high cholesterol) treatments, catapulting the company to a market cap in the hundreds of billions.</p>
<div class="lb-trans"><p>尽管 2024 年年末的业绩强劲，辉瑞在 2025 年仍在寻找立足之地，这得益于其 COVID 产品以及非 COVID 产品（如 Vyndaquel、Padcev 和 Eliquis）的销售超出预期。这家成立 176 年的大型制药公司在其行业中处于领先地位。辉瑞长期以来以大规模生产抗寄生虫药物 santonin、青霉素和抗生素而闻名，20 世纪后期辉瑞发明了伟哥（治疗勃起功能障碍）、佐洛夫（抗抑郁药）和立普妥（降胆固醇药物），使公司市值达到数千亿美元。</p>
</div><p>But over the past five years, the stock has let shareholders down despite paying a dividend with a current and substantial yield of 6.81%. Over that period, Pfizer has fallen more than 31%, and since its all-time high on December 17, 2021, shares of PFE are down more than 57%. <strong>24/7 Wall St.</strong> has performed analysis to provide prospective and investors with an idea of where the stock might be headed over the course of the next five years.</p>
<div class="lb-trans"><p>但在过去五年中，尽管辉瑞支付了当前收益率为 6.81% 的股息，股票仍让股东失望。在此期间，辉瑞的股价下跌超过 31%，自 2021 年 12 月 17 日的历史高点以来，PFE 的股价下跌超过 57%。<strong>24/7 Wall St.</strong> 进行了分析，以为潜在投资者提供对未来五年股票走势的想法。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://247wallst.com/wp-content/uploads/2025/01/Follow-Our-500000-AI-Portfolio-3.jpg" alt="" original-src="https://247wallst.com/wp-content/uploads/2025/01/Follow-Our-500000-AI-Portfolio-3.jpg"/></p>
<h2>Key Points in This Article:</h2>
<div class="lb-trans"><h2>本文的关键点：</h2>
</div><ul>
<li>Pfizer forecasts FY 2025 total revenues between $61 billion and $64 billion, with newly acquired drugs filling the gap for lagging COVID products such as Paxlovid.</li>
<li>Oncology sales, which comprise around 25% of the company’s revenues, are expected to grow with several drugs not only in the pipeline but in late-stage development.</li>
<li>If you’re looking for a megatrend with massive potential, make sure to grab a complimentary copy of our <strong>“The Next NVIDIA” report</strong>. This report breaks down AI stocks with 10x potential and will give you a huge leg up on profiting from this massive sea change.</li>
</ul>
<div class="lb-trans"><ul>
<li>辉瑞预测 2025 财年的总收入将在 610 亿美元至 640 亿美元之间，新获得的药物将填补 COVID 产品（如 Paxlovid）滞后的空缺。</li>
<li>肿瘤学销售预计将增长，约占公司收入的 25%，有多种药物不仅在研发中，还处于后期开发阶段。</li>
<li>如果您正在寻找具有巨大潜力的重大趋势，请确保获取我们 <strong>“下一个 NVIDIA” 报告</strong> 的免费副本。该报告详细分析了具有 10 倍潜力的 AI 股票，并将为您在这一重大变革中获利提供巨大的帮助。</li>
</ul>
</div><h2>Pfizer’s Recent Stock Success</h2>
<div class="lb-trans"><h2>辉瑞近期股票成功</h2>
</div><p>As a legacy drugmaker, Pfizer is a household name and fixture in both buy-and-hold and income portfolios. In 2024, the company returned $9.5 billion directly to shareholders through dividends. Over the past 40 years, the stock has gained 1,139%. In 2014, Pfizer purchased Innopharma and Baxter International’s vaccine portfolio. In 2016, it acquire Anacor Pharmaceuticals. And in 2019, the company purchased Therachon. However, over the past three years, shares have struggled.</p>
<div class="lb-trans"><p>作为一家传统制药公司，辉瑞是家喻户晓的名字，既是买入持有型投资组合的固定成分，也是收入型投资组合的常客。在 2024 年，公司通过股息直接向股东返还了 95 亿美元。在过去 40 年中，辉瑞的股价上涨了 1139%。2014 年，辉瑞收购了 Innopharma 和 Baxter International 的疫苗组合。2016 年，它收购了 Anacor Pharmaceuticals。2019 年，公司收购了 Therachon。然而，在过去三年中，辉瑞的股价表现不佳。</p>
</div><table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Fiscal Year</strong></td>
<td><strong>Price</strong></td>
<td><strong>Revenues</strong></td>
<td><strong>Net Income</strong></td>
</tr>
<tr>
<td>2015</td>
<td>$30.63</td>
<td>$48.851 B</td>
<td>$6.960 B</td>
</tr>
<tr>
<td>2016</td>
<td>$30.82</td>
<td>$52.824 B</td>
<td>$7.215 B</td>
</tr>
<tr>
<td>2017</td>
<td>$34.36</td>
<td>$52.546 B</td>
<td>$21.308 B</td>
</tr>
<tr>
<td>2018</td>
<td>$41.41</td>
<td>$40.825 B</td>
<td>$11.153 B</td>
</tr>
<tr>
<td>2019</td>
<td>$37.17</td>
<td>$40.905 B</td>
<td>$16.026 B</td>
</tr>
<tr>
<td>2020</td>
<td>$36.81</td>
<td>$41.651 B</td>
<td>$9.159 B</td>
</tr>
<tr>
<td>2021</td>
<td>$59.05</td>
<td>$81.288 B</td>
<td>$21.979 B</td>
</tr>
<tr>
<td>2022</td>
<td>$51.24</td>
<td>$100.330 B</td>
<td>$31.372 B</td>
</tr>
<tr>
<td>2023</td>
<td>$28.79</td>
<td>$58.496 B</td>
<td>$2.119 B</td>
</tr>
<tr>
<td>2024</td>
<td>$26.53</td>
<td>$55.166 B</td>
<td>-$2.595 B</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>财年</strong></td>
<td><strong>价格</strong></td>
<td><strong>收入</strong></td>
<td><strong>净收入</strong></td>
</tr>
<tr>
<td>2015</td>
<td>$30.63</td>
<td>$48.851 B</td>
<td>$6.960 B</td>
</tr>
<tr>
<td>2016</td>
<td>$30.82</td>
<td>$52.824 B</td>
<td>$7.215 B</td>
</tr>
<tr>
<td>2017</td>
<td>$34.36</td>
<td>$52.546 B</td>
<td>$21.308 B</td>
</tr>
<tr>
<td>2018</td>
<td>$41.41</td>
<td>$40.825 B</td>
<td>$11.153 B</td>
</tr>
<tr>
<td>2019</td>
<td>$37.17</td>
<td>$40.905 B</td>
<td>$16.026 B</td>
</tr>
<tr>
<td>2020</td>
<td>$36.81</td>
<td>$41.651 B</td>
<td>$9.159 B</td>
</tr>
<tr>
<td>2021</td>
<td>$59.05</td>
<td>$81.288 B</td>
<td>$21.979 B</td>
</tr>
<tr>
<td>2022</td>
<td>$51.24</td>
<td>$100.330 B</td>
<td>$31.372 B</td>
</tr>
<tr>
<td>2023</td>
<td>$28.79</td>
<td>$58.496 B</td>
<td>$2.119 B</td>
</tr>
<tr>
<td>2024</td>
<td>$26.53</td>
<td>$55.166 B</td>
<td>-$2.595 B</td>
</tr>
</tbody>
</table>
</div><p>Shares of PFE gained 20.17% in the five years leading up to the emergence of COVID-19. As one of the big three winners of the pandemic’s vaccine race, the stock took a big step forward in 2021, ending the year with a 60.41% gain. But since the end of 2022, that effect has faded and shares have come back down to Earth. However, there are some tailwinds that could see Pfizer’s stock rebound over the next several years.</p>
<div class="lb-trans"><p>在 COVID-19 出现之前的五年中，PFE 的股价上涨了 20.17%。作为疫情疫苗竞赛的三大赢家之一，该股在 2021 年大幅上涨，年末时上涨了 60.41%。但自 2022 年底以来，这一效应逐渐消退，股价回落。然而，有一些顺风因素可能会使辉瑞的股价在未来几年反弹。</p>
</div><h2>Key Drivers of Pfizer’s Stock Performance</h2>
<div class="lb-trans"><h2>辉瑞股票表现的关键驱动因素</h2>
</div><p><strong>1. Moving on From COVID:</strong> During its Q4 2024 earnings call, CFO Dave Denton said “our revenue volatility is largely int he past as COVID-related uncertainties have diminished.” With COVID cases continuing to plummet, the company is able to refocus (and reallocate CapEx) towards a suite of non-COVID and oncological drugs — something Denton says is expected to “set the stage for ongoing margin expansion.” Pfizer has a number of precious oncology drugs in development, and that facet of the drug market is expected to undergo an 8.1% compound annual growth rate (CAGR) from 2025 to 2030. Additionally, the company’s non-COVID drug products rose 12% in 2024, exceeding guidance of 9% to 11%.</p>
<div class="lb-trans"><p><strong>1. 摆脱 COVID 的影响：</strong> 在 2024 年第四季度的财报电话会议上，首席财务官 Dave Denton 表示：“我们的收入波动性在很大程度上已经过去，因为与 COVID 相关的不确定性已经减少。” 随着 COVID 病例持续下降，公司能够重新聚焦（并重新分配资本支出）于一系列非 COVID 和肿瘤药物——Denton 表示，这预计将 “为持续的利润扩张奠定基础。” 辉瑞正在开发多种珍贵的肿瘤药物，该药物市场预计将在 2025 年至 2030 年间实现 8.1% 的复合年增长率（CAGR）。此外，公司非 COVID 药物产品在 2024 年增长了 12%，超出了 9% 至 11% 的指导范围。</p>
</div><p><strong>2. Expanding Demand for Obesity Drugs:</strong> Despite its late entry in the obesity drug arena, which resulted in Pfizer ceding considerable market share to Novo Nordisk’s Ozempic, Pfizer has advanced the development of its once-daily oral formulation, <em>dangulipron</em>. The company has referred to obesity as a key therapeutic area going forward. The obesity drug industry is forecast to expand at a considerable 22.3% CAGR from 2025 to 2030.</p>
<div class="lb-trans"><p><strong>2. 肥胖药物需求的扩大：</strong> 尽管辉瑞在肥胖药物领域的进入较晚，导致其将相当大的市场份额让给了诺和诺德的 Ozempic，但辉瑞已推进其每日一次口服制剂_dangulipron_的开发。公司将肥胖视为未来的一个关键治疗领域。肥胖药物行业预计将在 2025 年至 2030 年间实现 22.3% 的显著复合年增长率。</p>
</div><p><strong>3. Co-Marketed Drugs:</strong> Pfizer has teamed up with Bristol Myers Squibb, with which it co-markets the blood thinner Eliquis. That endeavor resulted in $1.83 billion in Q4 2024 alone, which marked a 14% year-over-year gain for the drug, and exceeded the $1.67 billion analysts were expecting. The anticoagulant market was valued at $34.8 billion in 2023 and is forecast to undergo a 10.2% CAGR from 2024 to 2030.</p>
<div class="lb-trans"><p><strong>3. 联合营销药物：</strong> 辉瑞与百时美施贵宝合作，共同营销抗凝血药物 Eliquis。这一合作在 2024 年第四季度带来了 18.3 亿美元的收入，同比增长 14%，超出了分析师预期的 16.7 亿美元。抗凝血药物市场在 2023 年的估值为 348 亿美元，预计在 2024 年至 2030 年间实现 10.2% 的复合年增长率。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://247wallst.com/wp-content/uploads/2022/01/imageForEntry4-6PZ.jpg" alt="" original-src="https://247wallst.com/wp-content/uploads/2022/01/imageForEntry4-6PZ.jpg"/></p>
<h2>Pfizer (PFE) Price Prediction 2025–2030</h2>
<div class="lb-trans"><h2>辉瑞（PFE）2025-2030 年价格预测</h2>
</div><p>The current consensus one-year price target for Pfizer, according to analysts, is $28.38, which represents 12.26% potential upside over the next 12 months based on PFE’s current share price. Of the 18 analysts covering Pfizer, the stock receives a consensus “Moderate Buy” rating, with five analysts assigning it as a “Buy,” 13 assigning it as a “Hold” and zero assigning it as a “Sell.”</p>
<div class="lb-trans"><p>根据分析师的共识，辉瑞当前的一年价格目标为 28.38 美元，这代表着在未来 12 个月内相较于 PFE 当前股价的 12.26% 的潜在上涨。在覆盖辉瑞的 18 位分析师中，该股获得了 “适度买入” 的共识评级，其中 5 位分析师给予 “买入” 评级，13 位给予 “持有” 评级，0 位给予 “卖出” 评级。</p>
</div><p>However, by the end of 2025, <strong>24/7 Wall St.</strong>‘s forecast projects shares of Pfizer to be trading for $33.60 based on a projected EPS of $2.80 and a forward price-to-earnings (P/E) ratio of 7.53. That price target represents 32.91% potential upside from today’s share price.</p>
<div class="lb-trans"><p>然而，到 2025 年底，<strong>24/7 Wall St.</strong> 的预测显示辉瑞的股票将以 33.60 美元的价格交易，基于预计每股收益（EPS）为 2.80 美元和前瞻市盈率（P/E）为 7.53。这个价格目标相较于今天的股价有 32.91% 的潜在上涨空间。</p>
</div><h2>Pfizer Stock Price Target for 2030</h2>
<div class="lb-trans"><h2>辉瑞股票价格目标到 2030 年</h2>
</div><p>Based on our analysis, <strong>24/7 Wall St.</strong> projects shares of Pfizer to be trading for $34.08 by the end of 2030. That price target is good for 34.81% potential upside from the stock’s price today.</p>
<div class="lb-trans"><p>根据我们的分析，<strong>24/7 Wall St.</strong> 预测辉瑞的股票到 2030 年底将以 34.08 美元的价格交易。这个价格目标相较于今天的股价有 34.81% 的潜在上涨空间。</p>
</div><table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Year</strong></td>
<td><strong>Price</strong></td>
<td><strong>%Change From Current Price</strong></td>
</tr>
<tr>
<td>2025</td>
<td>$33.60</td>
<td>32.91%</td>
</tr>
<tr>
<td>2026</td>
<td>$36.00</td>
<td>42.40%</td>
</tr>
<tr>
<td>2027</td>
<td>$36.72</td>
<td>45.25%</td>
</tr>
<tr>
<td>2028</td>
<td>$33.24</td>
<td>31.48%</td>
</tr>
<tr>
<td>2029</td>
<td>$32.64</td>
<td>29.11%</td>
</tr>
<tr>
<td>2030</td>
<td>$34.08</td>
<td>34.81%</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>年份</strong></td>
<td><strong>价格</strong></td>
<td><strong>与当前价格的变化百分比</strong></td>
</tr>
<tr>
<td>2025</td>
<td>$33.60</td>
<td>32.91%</td>
</tr>
<tr>
<td>2026</td>
<td>$36.00</td>
<td>42.40%</td>
</tr>
<tr>
<td>2027</td>
<td>$36.72</td>
<td>45.25%</td>
</tr>
<tr>
<td>2028</td>
<td>$33.24</td>
<td>31.48%</td>
</tr>
<tr>
<td>2029</td>
<td>$32.64</td>
<td>29.11%</td>
</tr>
<tr>
<td>2030</td>
<td>$34.08</td>
<td>34.81%</td>
</tr>
</tbody>
</table>
</div><p>The post Pfizer Inc. (NYSE: PFE) Price Prediction and Forecast 2025-2030 (July 2025) appeared first on 24/7 Wall St..</p>
<div class="lb-trans"><p>关于辉瑞公司（NYSE: PFE）2025-2030 年价格预测和展望的文章首次出现在 24/7 Wall St.上。</p>
</div>

Pfizer Inc. (NYSE: PFE) Price Prediction and Forecast 2025-2030 (July 2025)

- 辉瑞公司股价在过去一个月上涨 8.24%，年初至今损失降至 5.02%。  
- FDA 仅推荐 65 岁及以上老年人接种 COVID-19 疫苗，可能对辉瑞造成压力。  
- 分析师预计辉瑞 2025 年股价将达到 $33.60，潜在上涨 32.91%。

辉瑞公司（NYSE 代码：PFE）2025-2030 年价格预测及展望（2025 年 7 月）